The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial
暂无分享,去创建一个
Daniel Wolff | Steffen Fieuws | Carlos Graux | Fabienne Dobbels | Philippe Lewalle | F. Baron | F. Dobbels | H. Greinix | Stephanie J. Lee | A. Im | S. Fieuws | S. Pavletic | T. Kerre | P. Lewalle | Sabina De Geest | H. Schoemans | C. Graux | Rafael F. Duarte | Steven Z. Pavletic | D. Wolff | D. Selleslag | Dominik Selleslag | Hildegard Greinix | J. Maertens | Frédéric Baron | Helene M. Schoemans | Kathy Goris | Raf Van Durm | Annie Im | Xavier Poiré | Tessa Kerre | Johan A. Maertens | R. Duarte | X. Poiré | K. Goris | S. D. De Geest | Raf Van Durm
[1] B. Storer,et al. Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Rubio. eGVHD App: a new tool to improve graft-versus-host disease assessment , 2018, Haematologica.
[3] E. Holler,et al. EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.
[4] M. Perales,et al. Establishing a Standardized System to Capture Chronic GRAFT-Versus-Host Disease (GVHD) DATA in Accordance to the National Institutes of Health (NIH) Consensus Criteria , 2018 .
[5] F. Dobbels,et al. Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress , 2018, Bone Marrow Transplantation.
[6] K. Gwet. Testing the Difference of Correlated Agreement Coefficients for Statistical Significance , 2016, Educational and psychological measurement.
[7] F. Dobbels,et al. Development, preliminary usability and accuracy testing of the EBMT ‘eGVHD App’ to support GvHD assessment according to NIH criteria—a proof of concept , 2016, Bone Marrow Transplantation.
[8] M. Horowitz,et al. Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network , 2016 .
[9] D. Porter,et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] Daniel Wolff,et al. Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .
[11] M. Robin,et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[13] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] Y. Efebera,et al. Improved accuracy of acute graft-versus-host disease staging among multiple centers. , 2014, Best practice & research. Clinical haematology.
[15] Li Li,et al. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] E. Holler,et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] Alexander von Eye,et al. On the Marginal Dependency of Cohen’s κ , 2008 .
[18] H. Deeg,et al. How I treat refractory acute GVHD. , 2007, Blood.
[19] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] J. Wagner,et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] K. Sullivan,et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.
[22] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.